Hery Poerwosusanta, Z. Noor, Karyono Mintaroem, E. Widjajanto, Mulyohadi Ali
{"title":"Extraction the Dayak Onion (Eleutherine sp): Scientific Based Herbal Medicine (OHT) Production Protocol","authors":"Hery Poerwosusanta, Z. Noor, Karyono Mintaroem, E. Widjajanto, Mulyohadi Ali","doi":"10.20527/JBK.V15I2.7263","DOIUrl":null,"url":null,"abstract":"Abstract: Indonesia has the second largest tropical forest and the richest in flora biodiversity in the world. Based on the Basic Health Research 2010, 59.29% of Indonesian had consumed herbal medicine, noted that Indonesian had consumed herb since the VIII century. Dayak onion (Eleutherine sp) widely used as traditional medicine, as a bahimang /wound healing agent. Dayak onion is not reassured as a medical treatment and lacked scientific evidence. Until 2018, thousands of herbs consumed by Indonesian, only 85 ingredients clinically tested. Sixty-four herbs have been pre-clinically tested and designated as Scientific based Herbal Medicines/Obat Herbal Terstandar (OHT) and 21 herbs have been tested clinically and determined as Phytopharmaca by the Badan Pengawasan Obat dan Makanan Republik Indonesia (BPOM-RI). Based on the data, the Dayak onion appointed as a Scientific based Herbal medicine (OHT) based on pre-clinical and phase 0 clinical research. Potential and promising for the treatment of metabolic, degenerative, catastrophic, neoplasmic, genetic and infectious diseases, Dayak onions can be developed into phytopharmaca in the future. The study aim is to make guidelines for the standardized herbal medicines development according to the rules and regulations. Keywords: Dayak Onion, Eleutherine sp, Scientific based Herbal Medicines, Phytopharmaca, Pre Clinic and Clinical Trials phases","PeriodicalId":53378,"journal":{"name":"Berkala Kedokteran","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Berkala Kedokteran","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20527/JBK.V15I2.7263","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
Abstract
Abstract: Indonesia has the second largest tropical forest and the richest in flora biodiversity in the world. Based on the Basic Health Research 2010, 59.29% of Indonesian had consumed herbal medicine, noted that Indonesian had consumed herb since the VIII century. Dayak onion (Eleutherine sp) widely used as traditional medicine, as a bahimang /wound healing agent. Dayak onion is not reassured as a medical treatment and lacked scientific evidence. Until 2018, thousands of herbs consumed by Indonesian, only 85 ingredients clinically tested. Sixty-four herbs have been pre-clinically tested and designated as Scientific based Herbal Medicines/Obat Herbal Terstandar (OHT) and 21 herbs have been tested clinically and determined as Phytopharmaca by the Badan Pengawasan Obat dan Makanan Republik Indonesia (BPOM-RI). Based on the data, the Dayak onion appointed as a Scientific based Herbal medicine (OHT) based on pre-clinical and phase 0 clinical research. Potential and promising for the treatment of metabolic, degenerative, catastrophic, neoplasmic, genetic and infectious diseases, Dayak onions can be developed into phytopharmaca in the future. The study aim is to make guidelines for the standardized herbal medicines development according to the rules and regulations. Keywords: Dayak Onion, Eleutherine sp, Scientific based Herbal Medicines, Phytopharmaca, Pre Clinic and Clinical Trials phases
摘要:印度尼西亚拥有世界上第二大热带森林和最丰富的植物多样性。根据2010年基础卫生研究,59.29%的印度尼西亚人食用草药,并指出印度尼西亚人自8世纪以来一直食用草药。大葱(Eleutherine sp .)作为传统医学广泛使用,作为伤口愈合剂。达雅洋葱作为一种医疗手段并不可靠,也缺乏科学依据。直到2018年,印尼人消费的数千种草药中,只有85种成分经过临床测试。64种草药已通过临床前试验并被指定为科学草药/Obat草药标准(OHT), 21种草药已通过临床试验并被印度尼西亚Badan Pengawasan Obat dan Makanan republic (BPOM-RI)确定为Phytopharmaca。基于这些数据,大葱被指定为基于临床前和0期临床研究的科学草药(OHT)。在代谢性疾病、退行性疾病、突变性疾病、肿瘤疾病、遗传疾病和感染性疾病的治疗方面,大葱具有潜在的潜力和发展前景,未来可开发成植物药。本研究的目的是为中药规范化开发提供依据。关键词:大葱,绿葱,科学草药,植物药,临床前和临床试验阶段